Avalyn Pharma Inc. IPO - What You Need to Know

Thinking about jumping into the Avalyn Pharma IPO? Before you put your hard-earned money on the line, let’s break down what this company does in plain English.

Disclaimer: I am an AI, not a financial advisor. IPOs are risky, so please do your own research or talk to a professional before investing.

1. What does this company actually do?

Avalyn Pharma develops treatments for severe lung diseases, specifically Idiopathic Pulmonary Fibrosis (IPF). Current oral pills for these conditions often cause harsh side effects, such as severe nausea, which forces many patients to stop treatment entirely.

Avalyn uses a proprietary nebulizer to deliver proven drugs directly into the lungs. By targeting the lungs instead of the whole body, they aim to make these life-extending treatments easier for patients to tolerate.

2. How do they make money and are they growing?

Avalyn does not sell any products yet and is currently pre-revenue. They reported a loss of about $78.4 million in 2023, up from $62.1 million in 2022. Their "growth" is measured by the progress of their clinical pipeline rather than sales:

• AP01 (Inhaled Pirfenidone): Their lead project. Early studies showed fewer stomach issues than the oral version. They are currently running a major clinical trial, with results expected in late 2027.
• AP02 (Inhaled Nintedanib): Targets patients with lung scarring. They are currently testing this in a global study, with results expected in late 2027.
• AP03 (Inhaled Combination Therapy): An early-stage project aiming to deliver two drugs in one inhalation. They plan to start testing in 2026.

3. What will they do with the money from this IPO?

Avalyn will use the cash to fund their research and development. Specifically, they plan to:

• Run Clinical Trials: Pay for the expensive process of recruiting patients and analyzing data for AP01 and AP02.
• Scale Manufacturing: Build more of their specialized nebulizer devices for upcoming trials.
• General Business Needs: Cover regulatory filings, patent protection, and daily operating costs.

4. What are the main risks I should worry about?

Biotech investing is high-stakes. Consider these risks before buying in:

• Success Depends on Trials: The company’s value rests almost entirely on the success of AP01 and AP02. If these trials fail to meet their goals, the company may have no path to profit, and you could lose your investment.
• Cash Burn and Dilution: The company spends over $70 million a year and has limited cash on hand. They will need to raise more money in the future. This means they will likely issue more shares, which reduces the value of your current holdings.
• Device Reliance: They rely on a specific nebulizer technology. If the manufacturer has supply issues or the device fails to perform as expected, their entire pipeline could stall.
• Regulatory Hurdles: Even with positive data, the FDA might demand more testing or limit how the drug is used, which could delay or prevent commercialization.

5. Where will it trade?

Avalyn plans to list on the Nasdaq under the ticker “AVLN.”

6. Final thought for a friend

Avalyn is trying to solve a major quality-of-life problem for patients with lung disease. By inhaling existing drugs, they hope to avoid the systemic side effects of pills. However, you are essentially betting on the success of long-term clinical trials and a complex supply chain.

The bottom line: This is a high-risk, high-reward play. Because their major trial results aren't expected until 2027, expect significant price volatility. If you decide to invest, make sure it’s an amount you are comfortable seeing fluctuate—or disappear—while the company works toward those critical milestones.